Physician profile
Michael Barrera
NPI 1669833232
$11,910.81
in general payments reported to CMS, 2019-2025
26 companies · $2,813 in 2025
The $2,813 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,309 · 2022: $2,259 · 2023: $2,585 · 2024: $2,946 · 2025: $2,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,090 · Education: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,089.54 |
| Education | $253.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,759.31 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,715.70 | 2021-2025 | |
| Janssen Biotech, INC. | $1,650.69 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,118.62 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,105.20 | 2021-2025 | |
| Pfizer INC. | $700.40 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $566.54 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $559.73 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $495.45 | 2021-2025 | Ilumya, Absorica Ld, Winlevi |
| Ucb, INC. | $333.73 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $292.29 | 2023-2025 | Zoryve |
| Amgen INC. | $252.23 | 2021-2023 | Otezla |
| Janssen Scientific Affairs, LLC | $242.77 | 2021 | |
| Incyte Corporation | $224.68 | 2021-2024 | Opzelura |
| Dermavant Sciences, INC. | $190.35 | 2023-2024 | Vtama |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $155.62 | 2021-2025 | |
| Galderma Laboratories, L.P. | $144.14 | 2023-2025 | Nemluvio, Aklief |
| Almirall LLC | $87.53 | 2021-2025 | Seysara |
| Leo Pharma INC. | $73.82 | 2021-2024 | Adbry |
| Botanix Sb INC | $69.20 | 2025 | Sofdra |
| Organon LLC | $48.32 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.14 | 2024 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.54 | 2021 | |
| Lnhc, INC | $21.35 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $19.77 | 2024 | Ycanth |
| Sanofi-Aventis U.S. LLC | $14.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Barrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.